Neurology and Neurosurgery

129-144 of 525

• 

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  NeuroFrontiers

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  Ashvini Keshavan, MRCP, PhD

  • 

    

    Ashvini Keshavan, MRCP, PhD

• 

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  On the Frontlines of Schizophrenia

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  Brian P. McDonough, MD, FAAFP; Ahmed Makhlouf, MD

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Ahmed Makhlouf, MD

• 

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  NeuroFrontiers

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  Hamid Abuwarda, PhD, BS

  • 

    

    Hamid Abuwarda, PhD, BS

• 

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  NeuroFrontiers

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  Sharon Sha, MD, MS

  • 

    

    Sharon Sha, MD, MS

• 

  RestartResume

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  RestartResume

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  Project Oncology®

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  Alexandria May, PharmD, BCPS; Angela Waanders, MD, MPH, MS

  • 

    

    Alexandria May, PharmD, BCPS

  • 

    

    Angela Waanders, MD, MPH, MS

  • 

    

    Ashley S. Margol, MD, MS

• 

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  NeuroFrontiers

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  Michael Weiss, MD

  • 

    

    Michael Weiss, MD

• 

  RestartResume

  Individualizing gMG Treatment: Defining Success With Each Patient

  RestartResume

  Individualizing gMG Treatment: Defining Success With Each Patient

  NeuroFrontiers

  Individualizing gMG Treatment: Defining Success With Each Patient

  Omar Sinno, MD

  • 

    

    Omar Sinno, MD

• 

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  NeuroFrontiers

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  Sheetal Shroff, MD

  • 

    

    Sheetal Shroff, MD

• 

  RestartResume

  Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape

  RestartResume

  Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape

  CME/CE

  Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape

  Stephen Chrzanowski, MD, PhD; Aravindhan Veerapandiyan, MD

  1.00 credit

  • 

    

    Stephen Chrzanowski, MD, PhD

  • 

    

    Aravindhan Veerapandiyan, MD

  1.00 credit

• 

  RestartResume

  Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

  RestartResume

  Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

  CME/CE

  Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

  Christoph U. Correll, MD; Jonathan M. Meyer

  0.25 credits

  • 

    

    Christoph U. Correll, MD

  • 

    

    Jonathan M. Meyer

  0.25 credits

• 

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  CME/CE

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  Neelam Goyal, MD; Christyn Edmundson, MD

  0.50 credits

  • 

    

    Neelam Goyal, MD

  • 

    

    Christyn Edmundson, MD

  0.50 credits

• 

  RestartResume

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  RestartResume

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  NeuroFrontiers

  Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT

  Ryan Quigley

  • 

    

    Ryan Quigley

• 

  RestartResume

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

  RestartResume

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

  NeuroFrontiers

  Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors

• 

  RestartResume

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

  RestartResume

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

  NeuroFrontiers

  LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

• 

  RestartResume

  Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment

  RestartResume

  Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment

  Global Neurology Academy

  Advancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment

  Tirisham V. Gyang, MD; Gates B. Colbert, MD

  • 

    

    Tirisham V. Gyang, MD

  • 

    

    Gates B. Colbert, MD

• 

  RestartResume

  Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care

  RestartResume

  Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care

  Global Neurology Academy

  Prevention on the Horizon: Early Intervention and Risk Reduction in MS Care

  Vikram V. Bhise, MD

  • 

    

    Vikram V. Bhise, MD

• Previous
• 1
• 2
• …
• 7
• 8
• 9
• 10
• 11
• …
• 32
• 33
• Next